Maia Biotechnology, INC 10-Q quarterly reports

MAIA Biotechnology, Inc. reports substantial progress in its Phase 2 and Phase 3 oncology trials, bolstered by significant capital raises, while continuing to navigate the inherent financial challenges of drug development.

MAIA Biotechnology, Inc. reported its first quarter 2026 financial results, highlighting increased operating expenses and significant cash inflow from financing activities, while advancing its lead oncology drug candidate, ateganosine.

MAIA Biotechnology reported increased operating expenses and a net loss for Q3 2025, while advancing its lead cancer drug ateganosine in clinical trials and adopting a new digital asset treasury plan.

MAIA Biotechnology reports progress in its lead lung cancer drug trials and secures new funding, despite ongoing financial challenges and a going concern warning.

MAIA Biotechnology announces its Q1 2025 financial results, showcasing advancements in its cancer immunotherapy programs and strategic collaborations.

MAIA Biotechnology's Q3 2024 report details financial results, clinical trial progress, and ongoing efforts to develop cancer therapies.

MAIA Biotechnology reports a net loss of $16.9 million for the first six months of 2024, while highlighting progress in its THIO-101 clinical trial and securing additional funding.

MAIA Biotechnology reports a net loss of $8.1 million for the first quarter of 2024, alongside updates on its clinical trial progress and recent financing activities.